Healthcare Equipment and Supplies
Company Overview of InSightec Ltd.
InSightec Ltd. Engages in the research, development, manufacture, and marketing of therapeutic magnetic resonance-guided focused ultrasound non-invasive surgery systems. Its magnetic resonance-guided focused ultrasound surgery technology combines a high intensity focused ultrasound beam that heats and destroys targeted tissue non-invasively, as well as visualizes patient anatomy, and controls the treatment by continuously monitoring the tissue effect. The company offers ExAblate O.R., a non-invasive operating room that incorporates interchangeable cradles offering commercially approved and research treatment options for a multitude of clinical indications, such as uterine fibroids, adenomyos...
5 Nahum Heth Street
Tirat Carmel, 39120
Founded in 1999
Key Executives for InSightec Ltd.
Founder and Chief Executive Officer
President and Chief Commercial Officer
Executive Chairman of the Board
Chief Financial Officer and Vice President
Vice President of Operations and Quality
Compensation as of Fiscal Year 2015.
InSightec Ltd. Key Developments
InSightec Ltd. Submits Pre Market Application for FDA Approval of Exablate Neuro for Treatment of Essential Tremor
Oct 22 15
Elbit Imaging Ltd. announced that it was informed by InSightec's Ltd., that it has submitted a premarket approval application (PMA) to the U.S. Food and Drug Administration (FDA) for its Exablate Neuro treatment of Essential Tremor. Exablate Neuro uses high intensity focused ultrasound to thermally ablate the target tissue and continuous MRI to visualize the anatomy, plan treatment and monitor treatment outcomes. In the brain, MRgFUS is used to perform a non-invasive thalamotomy through intact skull to relieve tremor in patients with Essential Tremor.
FDA Approves INSIGHTEC's Next Generation Exablate Fibroid Treatment System
Oct 7 15
INSIGHTEC announced that the United States Food and Drug Administration (FDA) has approved its next generation Exablate system to treat symptomatic uterine fibroids and changed the labeling to allow consideration for women who desire to maintain fertility. The updated labeling specifies that ablation of uterine fibroid tissue can now be considered for women with symptomatic uterine fibroids, who desire to retain fertility and spare their uterus. INSIGHTEC's Exablate therapy platform is transforming medicine by presenting a non-invasive treatment alternative that combines two technologies: Focused Ultrasound, which is used to ablate the fibroid tissue, and Magnetic Resonance Imaging (MRI), which is used to guide the ultrasound waves to the specific target tissue and provide real-time feedback on treatment progress and outcome. This change in labeling provides younger women suffering from symptomatic fibroids access to a new, non-invasive treatment option that is safe, effective and keeps their uterus intact without compromising their existing ability to get pregnant. Theapproval is based on accumulated, documented clinical dataon118 patients'pregnancies post Exablate MRgFUS treatments.
InSightec Ltd. Presents at 2015 BioFlorida Annual Conference, Oct-13-2015 10:05 AM
Sep 29 15
InSightec Ltd. Presents at 2015 BioFlorida Annual Conference, Oct-13-2015 10:05 AM. Venue: Omni Orlando Resort at ChampionsGate, 1500 Masters Blvd, ChampionsGate, FL 33896, United States. Speakers: Maurice R. Ferrér, Executive Chairman of the Board.
Similar Private Companies By Industry
Recent Private Companies Transactions
May 25, 2015